LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

RadNet to Present at the Bank of America Securities 2024 Health Care Conference on May 14th, 2024

May 13, 2024 | Last Trade: US$62.41 0.78 -1.23

LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Securities 2024 Health Care Conference in Las Vegas, NV on Tuesday, May 14, 2024 at 3:00 p.m. Pacific Time.

There will be simultaneous and archived webcasts available at https://bofa.veracast.com/webcasts/bofa/healthcare2024/id3dV364.cfm

Details for RadNet's Presentation:

Date:Tuesday, May 14, 2024
Time:3:00 p.m. Pacific Time
Location:Encore Hotel, Las Vegas, NV

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 375 owned and/or operated outpatient imaging centers. RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida, Texas and Arizona. In addition, RadNet provides radiology information technology and artificial intelligence solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,700 employees. For more information, visit http://www.radnet.com

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2800

Surmodics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB